valproic acid has been researched along with Cirrhosis in 18 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In this study we compared the effect of two HDAC inhibitors, trichostatin A and valproic acid, in an experimental model of kidney fibrosis." | 7.79 | Comparison of trichostatin A and valproic acid treatment regimens in a mouse model of kidney fibrosis. ( Geers, C; Mannaerts, I; Pauwels, M; Van Beneden, K; Van den Branden, C; van Grunsven, LA; Wissing, KM, 2013) |
| "Renal fibrosis is a common pathological feature of the progression of chronic kidney disease." | 5.46 | Valproic acid attenuates renal fibrosis through the induction of autophagy. ( Doi, S; Doi, T; Kawaoka, K; Masaki, T; Nakashima, A; Ueno, T; Yamada, K, 2017) |
| "The aim of present study was to investigate the effect of vitamin U (vit U, S-methylmethionine) on oxidative stress, inflammation, and fibrosis within the context of valproic acid (VPA)-induced renal damage." | 3.83 | Vitamin U has a protective effect on valproic acid-induced renal damage due to its anti-oxidant, anti-inflammatory, and anti-fibrotic properties. ( Bolkent, S; Ercin, M; Gezginci-Oktayoglu, S; Turkyilmaz, IB; Yanardag, R, 2016) |
| " In this study we compared the effect of two HDAC inhibitors, trichostatin A and valproic acid, in an experimental model of kidney fibrosis." | 3.79 | Comparison of trichostatin A and valproic acid treatment regimens in a mouse model of kidney fibrosis. ( Geers, C; Mannaerts, I; Pauwels, M; Van Beneden, K; Van den Branden, C; van Grunsven, LA; Wissing, KM, 2013) |
| " The effects of HDAC inhibitors in promoting the healing of wounds caused by radiation and in decreasing later skin fibrosis and tumorigenesis were correlated with suppression of the aberrant expression of radiation-induced transforming growth factor beta and tumor necrosis factor alpha." | 3.72 | Antitumor histone deacetylase inhibitors suppress cutaneous radiation syndrome: Implications for increasing therapeutic gain in cancer radiotherapy. ( Chung, YL; Wang, AJ; Yao, LF, 2004) |
| "Valproic acid is a first-line anti-epileptic drug and a proven HDAC inhibitor." | 2.53 | Anti-fibrotic effects of valproic acid: role of HDAC inhibition and associated mechanisms. ( Ahirwar, K; Jena, G; Khan, S, 2016) |
| "Valproic acid (VPA) has anticancer activity through regulation of cell differentiation and apoptosis via inhibition of histone deacetylase (HDAC) activity and is considered a class I HDAC inhibitor." | 1.48 | Inhibition of histone deacetylase 1 ameliorates renal tubulointerstitial fibrosis via modulation of inflammation and extracellular matrix gene transcription in mice. ( Kang, KP; Kim, D; Kim, W; Lee, S; Nguyễn-Thanh, T; Park, SK, 2018) |
| "Renal fibrosis is a common pathological feature of the progression of chronic kidney disease." | 1.46 | Valproic acid attenuates renal fibrosis through the induction of autophagy. ( Doi, S; Doi, T; Kawaoka, K; Masaki, T; Nakashima, A; Ueno, T; Yamada, K, 2017) |
| "Valproic acid (VPA) is a first-line drug used for the treatment of epilepsy and migraine as well as established as a HDAC inhibitor." | 1.42 | Sodium valproate ameliorates diabetes-induced fibrosis and renal damage by the inhibition of histone deacetylases in diabetic rat. ( Jena, G; Khan, S; Tikoo, K, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.56) | 18.2507 |
| 2000's | 5 (27.78) | 29.6817 |
| 2010's | 11 (61.11) | 24.3611 |
| 2020's | 1 (5.56) | 2.80 |
| Authors | Studies |
|---|---|
| Seet, LF | 2 |
| Chu, SW | 2 |
| Toh, LZ | 2 |
| Teng, X | 1 |
| Yam, GH | 1 |
| Wong, TT | 2 |
| Jung, H | 1 |
| Lee, E | 1 |
| Kim, I | 1 |
| Song, JH | 1 |
| Kim, GJ | 1 |
| Nguyễn-Thanh, T | 1 |
| Kim, D | 1 |
| Lee, S | 1 |
| Kim, W | 1 |
| Park, SK | 1 |
| Kang, KP | 1 |
| Van Beneden, K | 1 |
| Geers, C | 1 |
| Pauwels, M | 1 |
| Mannaerts, I | 1 |
| Wissing, KM | 1 |
| Van den Branden, C | 1 |
| van Grunsven, LA | 1 |
| Kee, HJ | 1 |
| Bae, EH | 1 |
| Park, S | 1 |
| Lee, KE | 1 |
| Suh, SH | 1 |
| Kim, SW | 1 |
| Jeong, MH | 1 |
| Patel, BM | 1 |
| Raghunathan, S | 1 |
| Porwal, U | 1 |
| Hannan, JL | 1 |
| Kutlu, O | 1 |
| Stopak, BL | 1 |
| Liu, X | 1 |
| Castiglione, F | 1 |
| Hedlund, P | 1 |
| Burnett, AL | 1 |
| Bivalacqua, TJ | 1 |
| Khan, S | 2 |
| Jena, G | 2 |
| Tikoo, K | 1 |
| Gezginci-Oktayoglu, S | 1 |
| Turkyilmaz, IB | 1 |
| Ercin, M | 1 |
| Yanardag, R | 1 |
| Bolkent, S | 1 |
| Finger, SN | 1 |
| Stefanovic, B | 1 |
| Ahirwar, K | 1 |
| Kawaoka, K | 1 |
| Doi, S | 1 |
| Nakashima, A | 1 |
| Yamada, K | 1 |
| Ueno, T | 1 |
| Doi, T | 1 |
| Masaki, T | 1 |
| Noh, H | 1 |
| Oh, EY | 1 |
| Seo, JY | 1 |
| Yu, MR | 1 |
| Kim, YO | 1 |
| Ha, H | 1 |
| Lee, HB | 1 |
| Chung, YL | 1 |
| Wang, AJ | 1 |
| Yao, LF | 1 |
| Minetti, GC | 1 |
| Colussi, C | 1 |
| Adami, R | 1 |
| Serra, C | 1 |
| Mozzetta, C | 1 |
| Parente, V | 1 |
| Fortuni, S | 1 |
| Straino, S | 1 |
| Sampaolesi, M | 1 |
| Di Padova, M | 1 |
| Illi, B | 1 |
| Gallinari, P | 1 |
| Steinkühler, C | 1 |
| Capogrossi, MC | 1 |
| Sartorelli, V | 1 |
| Bottinelli, R | 1 |
| Gaetano, C | 1 |
| Puri, PL | 1 |
| Lee, TM | 1 |
| Lin, MS | 1 |
| Chang, NC | 1 |
| Fukuda, Y | 1 |
| Watanabe, H | 1 |
| Ohtomo, Y | 1 |
| Yabuta, K | 1 |
| Taira, N | 1 |
| Nishi, H | 1 |
| Mano, M | 1 |
| Waki, N | 1 |
| Tsugita, Y | 1 |
| Takashima, S | 1 |
| Fukuda, K | 1 |
| Komatsubara, S | 1 |
2 reviews available for valproic acid and Cirrhosis
| Article | Year |
|---|---|
Anti-fibrotic effects of valproic acid: role of HDAC inhibition and associated mechanisms.
Topics: Animals; Cystic Fibrosis; Epigenesis, Genetic; Fibrosis; Histone Deacetylase Inhibitors; Humans; Kid | 2016 |
Pancreatitis induced by valproic acid: report of a case.
Topics: Adult; Anticonvulsants; Cholangiopancreatography, Endoscopic Retrograde; Chronic Disease; Female; Fi | 2001 |
16 other studies available for valproic acid and Cirrhosis
| Article | Year |
|---|---|
Valproic acid modulates collagen architecture in the postoperative conjunctival scar.
Topics: Cicatrix; Collagen; Conjunctiva; Fibroblasts; Fibrosis; Humans; Matrilin Proteins; Transforming Grow | 2022 |
Histone deacetylase inhibition has cardiac and vascular protective effects in rats with pressure overload cardiac hypertrophy.
Topics: Animals; Aorta; Arterial Pressure; Disease Models, Animal; Fibrosis; Gene Expression Regulation; His | 2019 |
Inhibition of histone deacetylase 1 ameliorates renal tubulointerstitial fibrosis via modulation of inflammation and extracellular matrix gene transcription in mice.
Topics: Animals; Cell Proliferation; Extracellular Matrix Proteins; Fibrosis; Histone Deacetylase 1; Histone | 2018 |
Comparison of trichostatin A and valproic acid treatment regimens in a mouse model of kidney fibrosis.
Topics: Acetylation; Animals; Doxorubicin; Female; Fibrosis; Glomerulosclerosis, Focal Segmental; Histone De | 2013 |
HDAC inhibition suppresses cardiac hypertrophy and fibrosis in DOCA-salt hypertensive rats via regulation of HDAC6/HDAC8 enzyme activity.
Topics: Animals; Cardiomegaly; Desoxycorticosterone Acetate; Disease Models, Animal; Enzyme Activation; Fibr | 2013 |
Cardioprotective effects of magnesium valproate in type 2 diabetes mellitus.
Topics: Animals; Animals, Newborn; Cardiotonic Agents; Cardiovascular Diseases; Diabetes Mellitus, Experimen | 2014 |
Valproic acid prevents penile fibrosis and erectile dysfunction in cavernous nerve-injured rats.
Topics: Animals; Blotting, Western; Erectile Dysfunction; Fibrosis; Histone Deacetylase Inhibitors; Histone | 2014 |
Sodium valproate ameliorates diabetes-induced fibrosis and renal damage by the inhibition of histone deacetylases in diabetic rat.
Topics: Acetylation; Acute Kidney Injury; Animals; Cytokines; Diabetes Mellitus, Experimental; Diabetic Neph | 2015 |
Vitamin U has a protective effect on valproic acid-induced renal damage due to its anti-oxidant, anti-inflammatory, and anti-fibrotic properties.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Blotting, Western; Catalase; Collagen Type I; Creat | 2016 |
Valproic acid suppresses collagen by selective regulation of Smads in conjunctival fibrosis.
Topics: Animals; Cells, Cultured; Collagen Type I; Conjunctiva; Enzyme Inhibitors; Fibroblasts; Fibrosis; Ge | 2016 |
Valproic acid attenuates renal fibrosis through the induction of autophagy.
Topics: Actins; Adenine; Animals; Autophagy; Cell Line; Collagen Type I; Cytoprotection; Disease Models, Ani | 2017 |
Histone deacetylase-2 is a key regulator of diabetes- and transforming growth factor-beta1-induced renal injury.
Topics: Acetylcysteine; Amides; Animals; Antioxidants; Biphenyl Compounds; Cell Line; Cell Transdifferentiat | 2009 |
Antitumor histone deacetylase inhibitors suppress cutaneous radiation syndrome: Implications for increasing therapeutic gain in cancer radiotherapy.
Topics: Acetylation; Animals; Antineoplastic Agents; Blotting, Northern; Blotting, Western; Cell Line, Tumor | 2004 |
Functional and morphological recovery of dystrophic muscles in mice treated with deacetylase inhibitors.
Topics: Animals; Dystrophin; Enzyme Inhibitors; Fibrosis; Follistatin; Hydroxamic Acids; Mice; Mice, Inbred | 2006 |
Inhibition of histone deacetylase on ventricular remodeling in infarcted rats.
Topics: Animals; Atrial Natriuretic Factor; Blotting, Western; Cardiomegaly; Cell Size; Collagen; Coronary V | 2007 |
Immunologically mediated chronic tubulo-interstitial nephritis caused by valproate therapy.
Topics: Anticonvulsants; Biopsy; Child; Complement C3; Fibrosis; Humans; Immunoglobulin G; Kidney; Male; Nep | 1996 |